JP2017522871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522871A5 JP2017522871A5 JP2017501287A JP2017501287A JP2017522871A5 JP 2017522871 A5 JP2017522871 A5 JP 2017522871A5 JP 2017501287 A JP2017501287 A JP 2017501287A JP 2017501287 A JP2017501287 A JP 2017501287A JP 2017522871 A5 JP2017522871 A5 JP 2017522871A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- region
- cdr2
- cdr1
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 200
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims description 45
- 229940127121 immunoconjugate Drugs 0.000 claims description 38
- 229940127089 cytotoxic agent Drugs 0.000 claims description 31
- 239000002254 cytotoxic agent Substances 0.000 claims description 29
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 29
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 18
- 108010023337 axl receptor tyrosine kinase Proteins 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 101150022345 GAS6 gene Proteins 0.000 claims description 8
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 8
- 230000000981 bystander Effects 0.000 claims description 8
- 108010093470 monomethyl auristatin E Proteins 0.000 claims description 8
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 108010059074 monomethylauristatin F Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- MSNVESLISHTIRS-UHFFFAOYSA-N 9h-pyrrolo[2,1-c][1,4]benzodiazepine Chemical compound N1=C2C=CC=CC2=CN2CC=CC2=C1 MSNVESLISHTIRS-UHFFFAOYSA-N 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 241000282567 Macaca fascicularis Species 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 230000003302 anti-idiotype Effects 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical group C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 claims description 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 239000012624 DNA alkylating agent Substances 0.000 claims description 2
- 241000206602 Eukaryota Species 0.000 claims description 2
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 claims description 2
- 101000923005 Homo sapiens Growth arrest-specific protein 6 Proteins 0.000 claims description 2
- 229930126263 Maytansine Natural products 0.000 claims description 2
- 102000029749 Microtubule Human genes 0.000 claims description 2
- 108091022875 Microtubule Proteins 0.000 claims description 2
- 208000002231 Muscle Neoplasms Diseases 0.000 claims description 2
- 230000004988 N-glycosylation Effects 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 2
- 102000004243 Tubulin Human genes 0.000 claims description 2
- 108090000704 Tubulin Proteins 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 108010044540 auristatin Proteins 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims description 2
- 229930195731 calicheamicin Natural products 0.000 claims description 2
- 229960002173 citrulline Drugs 0.000 claims description 2
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 2
- 201000010918 connective tissue cancer Diseases 0.000 claims description 2
- 239000003431 cross linking reagent Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims description 2
- 229930188854 dolastatin Natural products 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims description 2
- 229960005501 duocarmycin Drugs 0.000 claims description 2
- 229930184221 duocarmycin Natural products 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 208000010749 gastric carcinoma Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 210000004688 microtubule Anatomy 0.000 claims description 2
- 201000002077 muscle cancer Diseases 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000000498 stomach carcinoma Diseases 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 208000003200 Adenoma Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 238000012575 bio-layer interferometry Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201400380 | 2014-07-11 | ||
| DKPA201400380 | 2014-07-11 | ||
| DKPA201400489 | 2014-09-01 | ||
| DKPA201400489 | 2014-09-01 | ||
| DKPA201400746 | 2014-12-22 | ||
| DKPA201400746 | 2014-12-22 | ||
| DKPA201500283 | 2015-05-12 | ||
| DKPA201500283 | 2015-05-12 | ||
| PCT/EP2015/065900 WO2016005593A1 (en) | 2014-07-11 | 2015-07-10 | Antibodies binding axl |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020080943A Division JP2020141682A (ja) | 2014-07-11 | 2020-05-01 | Ａｘｌに結合する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522871A JP2017522871A (ja) | 2017-08-17 |
| JP2017522871A5 true JP2017522871A5 (enExample) | 2018-08-16 |
| JP6701162B2 JP6701162B2 (ja) | 2020-05-27 |
Family
ID=53673928
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017501287A Active JP6701162B2 (ja) | 2014-07-11 | 2015-07-10 | Ａｘｌに結合する抗体 |
| JP2020080943A Pending JP2020141682A (ja) | 2014-07-11 | 2020-05-01 | Ａｘｌに結合する抗体 |
| JP2023198745A Pending JP2024026158A (ja) | 2014-07-11 | 2023-11-24 | Ａｘｌに結合する抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020080943A Pending JP2020141682A (ja) | 2014-07-11 | 2020-05-01 | Ａｘｌに結合する抗体 |
| JP2023198745A Pending JP2024026158A (ja) | 2014-07-11 | 2023-11-24 | Ａｘｌに結合する抗体 |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US10512688B2 (enExample) |
| EP (2) | EP3763738A1 (enExample) |
| JP (3) | JP6701162B2 (enExample) |
| KR (2) | KR20230146665A (enExample) |
| CN (2) | CN114621347B (enExample) |
| AU (3) | AU2015286569B2 (enExample) |
| CA (1) | CA2952758A1 (enExample) |
| CY (1) | CY1122721T1 (enExample) |
| DK (1) | DK3169706T3 (enExample) |
| EA (1) | EA201790173A1 (enExample) |
| ES (1) | ES2774428T3 (enExample) |
| HR (1) | HRP20200283T1 (enExample) |
| HU (1) | HUE048667T2 (enExample) |
| IL (2) | IL296633A (enExample) |
| LT (1) | LT3169706T (enExample) |
| ME (1) | ME03665B (enExample) |
| MX (1) | MX370807B (enExample) |
| NZ (1) | NZ728019A (enExample) |
| PL (1) | PL3169706T3 (enExample) |
| PT (1) | PT3169706T (enExample) |
| RS (1) | RS60012B1 (enExample) |
| SG (2) | SG10202006715SA (enExample) |
| SI (1) | SI3169706T1 (enExample) |
| SM (1) | SMT202000265T1 (enExample) |
| UA (1) | UA127198C2 (enExample) |
| WO (1) | WO2016005593A1 (enExample) |
| ZA (1) | ZA201608609B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296633A (en) | 2014-07-11 | 2022-11-01 | Genmab As | Antibodies that bind axl |
| CA2991805A1 (en) * | 2015-07-10 | 2017-01-19 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
| JP2019505520A (ja) | 2016-01-13 | 2019-02-28 | ゲンマブ エー／エス | 抗体およびその薬物コンジュゲートの製剤 |
| KR102606938B1 (ko) | 2016-04-15 | 2023-11-29 | 바이오아트라, 인코퍼레이티드 | 항 Axl항체 및 이의 면역접합체와 이것들의 용도 |
| US11306153B2 (en) | 2016-05-20 | 2022-04-19 | Agency For Science, Technology And Research | Anti-AXL tyrosine kinase receptor antibodies and uses thereof |
| CN109311858B (zh) | 2016-05-26 | 2021-12-03 | 里科瑞尔姆Ip控股有限责任公司 | Egfr抑制剂化合物 |
| WO2018007592A1 (en) | 2016-07-08 | 2018-01-11 | Genmab A/S | New dosage regimens for antibody drug conjugates based on anti-axl antibodies |
| SG10202101958YA (en) * | 2016-08-31 | 2021-03-30 | Agency Science Tech & Res | Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc" and their uses thereof |
| CN108285487B (zh) * | 2017-01-08 | 2021-02-19 | 浙江昭华生物医药有限公司 | 抗5t4抗体-药物偶联物及其应用 |
| MX393780B (es) | 2017-01-17 | 2025-03-24 | Heparegenix Gmbh | Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos |
| SG11202002331QA (en) * | 2017-09-13 | 2020-04-29 | Nat Res Council Canada | Axl-specific antibodies and uses thereof |
| CN107987163B (zh) * | 2017-12-04 | 2018-11-20 | 杭州尚健生物技术有限公司 | 单克隆抗体9a及其应用 |
| MA52657A (fr) * | 2018-04-10 | 2021-02-17 | Genmab As | Anticorps spécifiques d'axl pour le traitement du cancer |
| CN110483639A (zh) * | 2018-05-15 | 2019-11-22 | 复旦大学 | 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途 |
| CA3104390A1 (en) | 2018-06-22 | 2019-12-26 | Genmab A/S | Method for producing a controlled mixture of two or more different antibodies |
| EP3856783A1 (en) * | 2018-09-26 | 2021-08-04 | Genmab A/S | Axl-specific antibodies for treatment of non-small cell lung cancer |
| AU2019372436A1 (en) * | 2018-11-01 | 2021-05-20 | Merck Patent Gmbh | Methods of administering anti-TIM-3 antibodies |
| US20220308062A1 (en) * | 2019-05-07 | 2022-09-29 | Board Of Regents, The University Of Texas System | Methods for predicting drug responsiveness in samples from cancer subjects |
| WO2021013746A1 (en) | 2019-07-19 | 2021-01-28 | Genmab A/S | Axl antibody-drug conjugates for use in treating cancer |
| CN112898414B (zh) * | 2019-12-04 | 2024-05-10 | 珠海泰诺麦博制药股份有限公司 | 抗人巨细胞病毒抗体及其用途 |
| US20230090552A1 (en) | 2020-01-08 | 2023-03-23 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
| US20230303675A1 (en) * | 2020-08-19 | 2023-09-28 | Pharmabcine Inc. | Modified antibody and method for manufacturing same |
| KR102549520B1 (ko) | 2021-01-29 | 2023-07-03 | 일리미스테라퓨틱스 주식회사 | 비염증성 식세포작용 유도 활성을 갖는 융합분자 |
| WO2022261846A1 (zh) * | 2021-06-16 | 2022-12-22 | 上海鑫湾生物科技有限公司 | 靶向axl蛋白的抗体及其抗原结合片段、其制备方法和应用 |
| EP4359439A1 (en) | 2021-06-24 | 2024-05-01 | Yeda Research and Development Co. Ltd | Combination therapy for the treatment of cancer comprising an anti-egfr antibody and an axl-inhibitor |
| US20260042848A1 (en) * | 2022-08-18 | 2026-02-12 | BioLegend, Inc. | Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same |
| PL446349A1 (pl) * | 2023-10-11 | 2025-04-14 | Celon Pharma Spółka Akcyjna | Przeciwciała bispecyficzne anty-AXL i anty-PD-L1 oraz ich zastosowanie w terapii, zwłaszcza w leczeniu nowotworu |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| ATE172879T1 (de) | 1989-08-09 | 1998-11-15 | Rhomed Inc | Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| JPH06508880A (ja) | 1991-07-08 | 1994-10-06 | ユニバーシティ オブ マサチューセッツ アット アムハースト | サーモトロピック液晶セグメント化ブロックコポリマー |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| DE60013773T2 (de) | 1999-02-03 | 2005-11-10 | Biosante Pharmaceuticals, Inc. | Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| IL147765A0 (en) | 1999-07-29 | 2002-08-14 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES TO HER2/neu |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US7129261B2 (en) | 2001-05-31 | 2006-10-31 | Medarex, Inc. | Cytotoxic agents |
| PT2314629E (pt) | 2002-07-18 | 2014-01-22 | Merus B V | Produção recombinante de misturas de anticorpos |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| CN107213469A (zh) | 2003-11-06 | 2017-09-29 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
| CA2617907A1 (en) | 2005-08-05 | 2007-02-15 | Syntarga B.V. | Triazole-containing releasable linkers and conjugates comprising the same |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| AU2006317242A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| CN101415679A (zh) | 2006-02-02 | 2009-04-22 | 辛塔佳有限公司 | 水溶性cc-1065类似物及其缀合物 |
| GEP20135917B (en) | 2006-03-17 | 2013-09-10 | Biogen Idec Inc | Stabilized polypeptide compositions |
| ES2395969T3 (es) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Dominios de proteínas heterodiméricas genéticamente modificados |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| EP2070956A1 (en) | 2007-12-14 | 2009-06-17 | Total Petrochemicals Research Feluy | Process for the production of a bimodal polypropylene having low ash content |
| ES2702087T3 (es) | 2007-06-21 | 2019-02-27 | Macrogenics Inc | Diacuerpos covalentes y sus usos |
| WO2009017394A1 (en) | 2007-08-01 | 2009-02-05 | Syntarga B.V. | Substituted cc-1065 analogs and their conjugates |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| TW200936160A (en) | 2007-11-15 | 2009-09-01 | Chugai Pharmaceutical Co Ltd | Monoclonal antibodies that bind to anexelekto and uses thereof |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
| CA2742568C (en) | 2008-11-03 | 2017-09-26 | Syntarga B.V. | Novel cc-1065 analogs and their conjugates |
| SG172254A1 (en) | 2008-12-19 | 2011-07-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| CN102459344A (zh) * | 2009-05-15 | 2012-05-16 | 中外制药株式会社 | 抗axl抗体 |
| AR077595A1 (es) * | 2009-07-27 | 2011-09-07 | Genentech Inc | Tratamientos de combinacion |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| US9074192B2 (en) | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| PL2560993T3 (pl) | 2010-04-20 | 2024-11-04 | Genmab A/S | Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania |
| CA2797981C (en) | 2010-05-14 | 2019-04-23 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| WO2011159980A1 (en) | 2010-06-18 | 2011-12-22 | Genentech, Inc. | Anti-axl antibodies and methods of use |
| RU2013110876A (ru) | 2010-08-24 | 2014-09-27 | Рош Гликарт Аг | Активируемые биспецифические антитела |
| RU2013110875A (ru) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| WO2012175692A1 (en) | 2011-06-22 | 2012-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-axl antibodies and uses thereof |
| JP6033293B2 (ja) | 2011-06-22 | 2016-11-30 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） | 抗Ａｘｌ抗体及びその使用 |
| EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| US9879061B2 (en) | 2011-12-15 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis |
| HK1208216A1 (en) | 2012-05-15 | 2016-02-26 | Concortis Biosystems, Corp | Drug-conjugates, conjugation methods, and uses thereof |
| US9624308B2 (en) | 2012-11-05 | 2017-04-18 | Pierre Fabre Medicament | Antigen binding proteins |
| WO2014174111A1 (en) | 2013-04-26 | 2014-10-30 | Pierre Fabre Medicament | Axl antibody-drug conjugate and its use for the treatment of cancer |
| GB201410825D0 (en) | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| IL296633A (en) | 2014-07-11 | 2022-11-01 | Genmab As | Antibodies that bind axl |
| ES2764299T3 (es) | 2014-12-09 | 2020-06-02 | Inst Nat Sante Rech Med | Anticuerpos monoclonales humanos contra AXL |
| CA2991805A1 (en) | 2015-07-10 | 2017-01-19 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
-
2015
- 2015-07-10 IL IL296633A patent/IL296633A/en unknown
- 2015-07-10 CN CN202210136603.9A patent/CN114621347B/zh active Active
- 2015-07-10 NZ NZ728019A patent/NZ728019A/en unknown
- 2015-07-10 WO PCT/EP2015/065900 patent/WO2016005593A1/en not_active Ceased
- 2015-07-10 SI SI201531118T patent/SI3169706T1/sl unknown
- 2015-07-10 RS RS20200253A patent/RS60012B1/sr unknown
- 2015-07-10 KR KR1020237033792A patent/KR20230146665A/ko active Pending
- 2015-07-10 LT LTEP15738884.4T patent/LT3169706T/lt unknown
- 2015-07-10 ES ES15738884T patent/ES2774428T3/es active Active
- 2015-07-10 PL PL15738884T patent/PL3169706T3/pl unknown
- 2015-07-10 SG SG10202006715SA patent/SG10202006715SA/en unknown
- 2015-07-10 EP EP19213033.4A patent/EP3763738A1/en active Pending
- 2015-07-10 AU AU2015286569A patent/AU2015286569B2/en active Active
- 2015-07-10 CA CA2952758A patent/CA2952758A1/en active Pending
- 2015-07-10 JP JP2017501287A patent/JP6701162B2/ja active Active
- 2015-07-10 ME MEP-2020-42A patent/ME03665B/me unknown
- 2015-07-10 HR HRP20200283TT patent/HRP20200283T1/hr unknown
- 2015-07-10 SG SG11201610777VA patent/SG11201610777VA/en unknown
- 2015-07-10 MX MX2016016881A patent/MX370807B/es active IP Right Grant
- 2015-07-10 SM SM20200265T patent/SMT202000265T1/it unknown
- 2015-07-10 DK DK15738884.4T patent/DK3169706T3/da active
- 2015-07-10 IL IL249512A patent/IL249512B2/en unknown
- 2015-07-10 PT PT157388844T patent/PT3169706T/pt unknown
- 2015-07-10 KR KR1020177003473A patent/KR102586656B1/ko active Active
- 2015-07-10 EA EA201790173A patent/EA201790173A1/ru unknown
- 2015-07-10 EP EP15738884.4A patent/EP3169706B1/en active Active
- 2015-07-10 HU HUE15738884A patent/HUE048667T2/hu unknown
- 2015-07-10 US US15/325,364 patent/US10512688B2/en active Active
- 2015-07-10 UA UAA201701193A patent/UA127198C2/uk unknown
- 2015-07-10 CN CN201580045131.4A patent/CN107074948B/zh active Active
-
2016
- 2016-12-13 ZA ZA2016/08609A patent/ZA201608609B/en unknown
-
2018
- 2018-03-28 US US15/938,961 patent/US10201607B2/en active Active
-
2019
- 2019-01-15 US US16/248,402 patent/US10765743B2/en active Active
- 2019-02-07 US US16/270,317 patent/US10500276B2/en active Active
- 2019-11-04 US US16/673,383 patent/US20200171152A1/en not_active Abandoned
-
2020
- 2020-03-04 CY CY20201100192T patent/CY1122721T1/el unknown
- 2020-05-01 JP JP2020080943A patent/JP2020141682A/ja active Pending
-
2021
- 2021-07-15 AU AU2021205074A patent/AU2021205074B2/en active Active
-
2023
- 2023-02-28 US US18/175,894 patent/US20240091352A1/en active Pending
- 2023-11-24 JP JP2023198745A patent/JP2024026158A/ja active Pending
-
2025
- 2025-03-10 AU AU2025201717A patent/AU2025201717A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522871A5 (enExample) | ||
| HRP20200283T1 (hr) | Protutijela koja se vežu na axl | |
| KR102190548B1 (ko) | 항-her2 항체-약물 접합체 | |
| WO2020114480A1 (en) | Anti-claudin antibodies and uses thereof | |
| JP2020501531A5 (enExample) | ||
| JP2018525354A5 (enExample) | ||
| JP2018520991A5 (enExample) | ||
| CN107735093A (zh) | Cd123抗体和其结合物 | |
| HRP20200551T1 (hr) | Axl-specifični konjugati protutijelo-lijek za liječenje raka | |
| JPWO2021142002A5 (enExample) | ||
| JP2010535713A5 (enExample) | ||
| CN116390772A (zh) | 新型美登素类似物作为adc有效载荷及其在癌症治疗中的用途 | |
| JP2026501556A (ja) | 抗体薬物複合体 | |
| JPWO2020176497A5 (enExample) | ||
| KR20240095534A (ko) | 화학요법 내성 암의 치료 방법에서 사용하기 위한 항체-약물 접합체 | |
| WO2024088388A1 (en) | Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof | |
| WO2024050031A2 (en) | Novel camptothecin derivatves as antibody-drug conjugates (adc) payloads | |
| CA3147887A1 (en) | Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas | |
| CN113329769A (zh) | 具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物 | |
| WO2024208354A1 (en) | Antibody drug conjugates | |
| NZ766131B2 (en) | Antibodies binding AXL | |
| NZ766128B2 (en) | Antibodies binding AXL | |
| JP2025529266A (ja) | ヒト化抗ｐｖｒ抗体の薬物複合体 | |
| WO2026011073A1 (en) | Antibody drug conjugates | |
| CA3289273A1 (en) | Combination of antibody-drug conjugate and other medicine |